TB-500 (Thymosin Beta-4)

43-amino acid peptide identical to endogenous thymosin beta-4. Sequesters G-actin monomers, promoting cell migration and tissue repair. Upregulates actin polymerization, driving wound healing, anti-inflammation, and new blood vessel formation at injury sites.

Half-life

2 hours

Bioavailability

Systemic via subcutaneous injection

Route

subcutaneous, intramuscular

Evidence tier

T2 — Single-RCT or mechanistic

Optimization pillars

recovery

References

2 peer-reviewed

Dose ranges

Three tiers ordered by aggressiveness. Tier chips on every OPTIMIZE intervention let you filter the catalog by your evidence tolerance.

conservative

2–2.5 mg twice/week

Maintenance recovery

moderate

2.5–5 mg twice/week

Active injury loading phase

aggressive

5–10 mg twice/week

Severe injury protocol (4-6 week loading)

Monitoring

hs-crp
wbc

Contraindications

active-cancer
pregnancy

References

PMID:20453902Thymosin beta 4 promotes dermal healing — Ann N Y Acad Sci, 2010
PMID:17371392Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair — Nature, 2007

Notes

TB-500 and BPC-157 work through completely different mechanisms. BPC-157 upregulates growth hormone receptors and VEGF. TB-500 drives actin polymerization and cell migration. Stacking them is not redundancy — it is two separate repair pathways running simultaneously. The loading-then-maintenance dosing pattern matters. Front-load for 4-6 weeks, then reduce. The cells need the migration signal at the beginning, not indefinitely.

This is not medical advice

Discuss with a licensed clinician before starting, stopping, or changing any compound. This page documents what the research literature describes — it is not a prescription.

See TB-500 (Thymosin Beta-4) in a protocol matched to you